MULTIPLE MYELOMA

November 20th 2024

Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple myeloma.

November 18th 2024

During a Case-Based Roundtable® event, Hana Safah, MD, examined several real-world studies of dose frequency and outpatient administration of teclistamab in patients with multiple myeloma in the first article of a 2-part series.

November 16th 2024

The key secondary end point of overall survival was met in the DREAMM-7 trial of belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma.

November 15th 2024

During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR T-cell therapies in multiple myeloma and beyond.